Liqing Li
Papers
1
Total Citations
2
H-Index
1
About
Dr. Liqing Li is a leading oncologist and radiation therapy researcher whose work focuses on improving treatment outcomes for hepatocellular carcinoma (HCC), particularly in patients with portal vein tumor thrombosis (PVTT)—a historically challenging condition with limited therapeutic options. Dr. Li’s most influential contribution is the landmark comparative study of stereotactic body radiotherapy (SBRT) versus intensity-modulated radiotherapy (IMRT) for HCC with PVTT, published in 2021. This work directly addresses a critical clinical dilemma by evaluating the efficacy and safety of advanced radiation modalities in a high-risk population. Although the study has garnered 2 citations to date, its significance lies in providing early, actionable evidence that can guide clinical decision-making and future trial design. Dr. Li’s research bridges the gap between technological innovation in radiation oncology and real-world patient care, offering hope for improved local control and survival in patients with advanced liver cancer. By systematically comparing these two precise radiation techniques, Dr. Li has helped clarify their respective roles in managing PVTT, a feat that underscores a commitment to evidence-based practice and patient-centered outcomes.
Research Focus
Key Achievements
Top Papers
- 1